ѻý

<ѻý class="page-title">Meeting Coverage

ADA

<ѻý class="page-description">American Diabetes Association
A Call to Action on Gestational Diabetes

Women are failed at every point, and earlier screening and later follow-up are needed, group says

ADA over a photo of Orange County Convention Center in Orlando, FL
<ѻý class="section_title">Latest ADA Meeting Coverage
Low-Dose SGLT2 Inhibitor May Protect Kidneys in Youth With T1D

Adolescence is a critical period in T1D, associated with hyperfiltration and high HbA1c levels

June 25, 2024
In-Hospital Continuous Glucose Monitoring Can't Budge T2D Control

Randomized trial failed to get anywhere near tight glucose control

June 25, 2024
Novel GLP-1/Glucagon Drug Promising for Weight Loss

Phase II data support testing pemvidutide for comorbid obesity and liver conditions

June 24, 2024
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2D

Insulin sensitivity also improved in people with obesity free of diabetes

June 23, 2024
Automated Insulin Pump Helps Type 2 Diabetes Control

SECURE-T2D trial provides pivotal findings to expand use of the Omnipod 5 System

June 23, 2024
Trial Points to Best Practices for Inhaled Insulin in Type 1 Diabetes

INHALE 3 provides insights into dosing and who might actually do worse than with a pump

June 23, 2024
Fenofibrate Slows Diabetic Retinopathy Progression

Randomized trial shows a benefit of an inexpensive cholesterol drug

June 22, 2024
Tirzepatide May Help Treat Sleep Apnea in People With Obesity

Zepbound met primary and secondary endpoints, with or without CPAP

June 21, 2024
Tech in Diabetes: What's Going Wrong?

FDA Commissioner Robert Califf, MD, talks tech

June 21, 2024
Diabetes Projected to Affect 1.3 Billion People by 2050

Advance of disease driven by high BMI, with social determinants of health playing a role

June 28, 2023
Protocol Optimizing Meds for T2D and CVD Pushed Beyond Cardiology Alone

Endocrinologists urged to pay attention to COORDINATE trial

June 27, 2023
Yet Another Injectable Combo Achieves Near 15% Weight Loss in Trial

But GI side effects higher than other comparable anti-obesity agents

June 27, 2023
Semaglutide Plus Cagrilintide Reduced Blood Sugar, Weight in T2D

Once-weekly CagriSema reduced body weight more than either agent alone

June 27, 2023
<ѻý class="section_title"> Latest Endocrinology Meeting Coverage